GlassScriptPhysician profile
Karthikeya Devireddy
NPI 1780615542
$2,935.14
in general payments reported to CMS, 2019-2025
30 companies · $725 in 2025
The $725 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $41.26 · 2021: $445 · 2022: $211 · 2023: $425 · 2024: $733 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $532.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $436.59 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $255.98 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.92 | 2021-2024 | Jardiance |
| Amgen INC. | $184.34 | 2019-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $176.68 | 2019-2022 | |
| Pfizer INC. | $171.71 | 2019-2025 | |
| Astellas Pharma US INC | $132.79 | 2023-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $111.55 | 2019-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Medtronic, INC. | $82.42 | 2023-2024 | Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $78.32 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.75 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.57 | 2021-2025 | Xifaxan |
| Organon LLC | $45.10 | 2021 | |
| Qiagen, LLC | $32.22 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $31.94 | 2025 | The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $31.46 | 2024 | Rexulti |
| Baxter Healthcare | $28.36 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Corcept Therapeutics | $28.04 | 2024 | Korlym |
| Glaxosmithkline, LLC. | $28.01 | 2023 | Shingrix, Arexvy |
| Optinose US, INC. | $23.31 | 2023 | |
| Mylan Specialty L.P. | $22.77 | 2024 | Yupelri |
| Abbott Laboratories | $22.73 | 2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $22.30 | 2019 | |
| Shield Therapeutics INC | $22.19 | 2023 | Accrufer |
| Biomerieux INC | $21.00 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Dexcom, INC. | $17.41 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $16.24 | 2021 | |
| Phadia US INC. | $16.24 | 2019 | |
| Abbvie INC. | $13.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karthikeya Devireddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.